Market closed
Inozyme Pharma/$INZY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inozyme Pharma
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
Ticker
$INZY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
67
Website
Inozyme Pharma Metrics
BasicAdvanced
$69M
-
-$1.62
1.31
-
Price and volume
Market cap
$69M
Beta
1.31
52-week high
$7.80
52-week low
$0.98
Average daily volume
604K
Financial strength
Current ratio
3.56
Quick ratio
3.35
Long term debt to equity
54.401
Total debt to equity
81.059
Interest coverage (TTM)
-18.72%
Management effectiveness
Return on assets (TTM)
-40.13%
Return on equity (TTM)
-102.90%
Valuation
Price to book
1.2
Price to tangible book (TTM)
1.2
Price to free cash flow (TTM)
-0.738
Growth
Earnings per share change (TTM)
18.31%
3-year earnings per share growth (CAGR)
-12.25%
What the Analysts think about Inozyme Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Inozyme Pharma stock.
Inozyme Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Inozyme Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Inozyme Pharma News
AllArticlesVideos
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
GlobeNewsWire·4 days ago
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewsWire·3 weeks ago
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Inozyme Pharma stock?
Inozyme Pharma (INZY) has a market cap of $69M as of March 14, 2025.
What is the P/E ratio for Inozyme Pharma stock?
The price to earnings (P/E) ratio for Inozyme Pharma (INZY) stock is 0 as of March 14, 2025.
Does Inozyme Pharma stock pay dividends?
No, Inozyme Pharma (INZY) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Inozyme Pharma dividend payment date?
Inozyme Pharma (INZY) stock does not pay dividends to its shareholders.
What is the beta indicator for Inozyme Pharma?
Inozyme Pharma (INZY) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.